Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) EPS (Weighted Average and Diluted) (2021 - 2026)

Heron Therapeutics filings provide 6 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.04 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 500.0% to -$0.04 in Q1 2026 year-over-year; TTM through Mar 2026 was -$0.17, a 183.33% decrease, with the full-year FY2025 number at -$0.12, down 33.33% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.04 in Q1 2026 for Heron Therapeutics, down from -$0.01 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.02 in Q4 2024 to a low of -$0.63 in Q1 2022.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.06 (2024), compared with a mean of -$0.16.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): surged 150.0% in 2025 and later crashed 500.0% in 2026.
  • Heron Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.13 in 2022, then surged by 61.54% to -$0.05 in 2023, then surged by 140.0% to $0.02 in 2024, then crashed by 150.0% to -$0.01 in 2025, then tumbled by 300.0% to -$0.04 in 2026.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.04 (Q1 2026), -$0.01 (Q4 2025), and -$0.1 (Q3 2025) per Business Quant data.